Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1993-09-03
1998-04-28
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514255, 514908, 514974, A61K 31495, A61K 3170
Patent
active
057444552
ABSTRACT:
Disclosed is a method for preventing cardiotoxicity in a human in need of such preventive treatment, the method including administering an effective amount of a bisdioxopiperazine. Also disclosed is a method for preventing cardiotoxicity induced by the administration of an anthracycline. Further, a tumoricidal, cardioprotective combination of agents is disclosed.
REFERENCES:
patent: 4275063 (1981-06-01), Creighton
patent: 4755619 (1988-07-01), Creighton et al.
patent: 4764614 (1988-08-01), Miller
patent: 4963551 (1990-10-01), Palepu et al.
patent: 4963679 (1990-10-01), Tu et al.
patent: 5242901 (1993-09-01), Speyer et al.
Doroshow JH, Locker GY, Myers CE: Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J. Clin. Invest. 1980;65:129-135.
Olson RD, Boerth RC, Gerber JG, Nies AS: Mechanism of Adriamycin cardiotoxicity: evidence for oxidative stress. Life Sciences 1981;29:1393-1401.
Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formulation in rat heart. Cancer Research 1983;43:460-472.
Gutteridge JMC: Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron(III) complex. Biochem. Phar. 1984;33(11):1725-1728.
Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow GH, Daniels JR: Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. JCP 1980;2:487-515.
Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, Daniels JR: Anthracycline-associated cardiac and renal damage in rabbits. Lab. Invest. 1981;45(2):157162, 157164.
Decorti G, Klugmann FB, Candussio L, Basa M, Mallardi F, Grill V, Baldini L: Effect of polyethylene glycol 400 on Adriamycin induced histamine release. Eur. J. Cancer Clin. OncoL 1986;22(7):793-799.
Klugmann FB, Decorti G, Candussio L, Grill V, Mallardi F, Baldini L: Inhibitors of Adriamycin-induced histamine release in vitro limit Adriamycin cardiotoxicity in vivo. Br. J. Cancer 1986;54:743-748.
Decorti G, Klugmann FB, Candussio L, Baldini L: Characterization of histamine secretion induced by anthracyclines in rat peritoneal mast cells. Biochem. Pharm. 1986;35(12):1939-1942.
Olson HM, Young DM, Prieur DJ, LeRoy AF, Reagan RL: Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Amer. J. Pathol. 1974;77:439-454.
Zorzato F, Saiviati G, Facchinetti T, Volpe P: Doxorubicin induces calcium release from terminal cisternae of skeletal muscle: a study on isolated sarcoplasmic reticulum and chemically skinned fibers. J. Biol. Chem. 1985;260(12):7349-7355.
Caroni P, Villani F, Carafoli E: The cardiotoxic antibiotic doxorubicin inhibits the Na.sup.+ /Ca.sup.2+ exchange of dog heart sarcolemmal vesicles. Elsevier 1981;130(2):184-188.
Anghileri LJ: Ca.sup.2+ -Transport inhibition by the antitumor agents Adriamycin and daunomycin. Arzneim.-Forsch./Drug Res. 1977;27(1),6:1177-1180.
Boucek RJ, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S: The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: a correlative study of cardiac muscle with isolated membrane fractions. J. Biol. Chem. 1987;262(33):15851-15856.
Tomlinson CW, Godin DV, Rabkin SW: Adriamycin cardiomyopathy: implications of cellular changes in a canine model with mild impairment of left ventricular function. Biochem. Pharm. 1985;34(22):4033-4041.
Iwamoto Y, Hansen IL, Porter TH, et al: Inhibition of coenzyme Q.sub.10 -enzymes, succinoxidase and NADH-oxidase, by Adriamycin and other quinones having antitumor activity. Biochem. Biophys. Res. Commun. 1974;58:633-638.
Bertazzoli C, Ghione M: Adriamycin associated cardiotoxicity: research on prevention with coenzyme Q. Pharm. Res. Comm. 1977;9(3):235-244.
Zbinden G, Bachmann E, Bolliger H: Study of coenzyme Q in toxicity of Adriamycin. 1977 Elsevier/North-Holland Biomedical Press, p. 219.
Combs AB, Acosta D, Folkers K: Prevention by coenzyme Q.sub.10 of the cardiotoxicity of Adriamycin in cultured heart cells. IRCS Med. Sci. 1976;4:403.
Rosenoff SH, Brooks E, Bostick F, Young RC: Alterations in DNA synthesis in cardiac tissue induced by Adriamycin in vivo-Relationship to fatal toxicity. Biochem. Pharm. 1971;24:18981901.
Arena E, D'Alessandro N, Dusonchet L, Gebbia N, Gerbasi F, Sanguedolce R, Rausa L: Influence of pharmacokinetic variations on the pharmacological properties of Adriamycin. (Univ. Palermo). (Not dated).
Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW, Billingham ME: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann. Intern. Med. 1983;99(6):745-749.
Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 1982;96:133-139.
Weiss AJ, Metter GE, Fletcher WS, Wilson WL, Grage TB, Ramirez G: Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Rep. 1976;60:813-822.
Weiss AJ, Manthel RW: Experience with the use of Adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer 1977;40:2046-52.
Byfield JE, Seagren S, Chan PYM: Adriamycin (AD) cardiotoxicity (CT): clues to mitigation. ASCO Abstracts 1977;Mar.:275.
Nagineni CN, Yamada T, Yang JJ, Seraydarian MW: Effects of Adriamycin on enzymes of adenine nucleotide metabolism in heart cell cultures. Res. Commun. Chem. Path. Pharm. 1985;50(2):301305.
Pelikan PCD, Weisfeldt ML, Jacobus WE, Miceli MV, Bulkley BH, Gerstenblith G: Acute doxorubicin cardiotoxicity: functional, metabolic, and morphologic alterations in the isolated, perfused rat heart. J. Cardiovasc. Pharm. 1986;8:1058-1066.
Gibbs CL: Acute energetic effects of daunomycin on rabbit heart muscle. J. Cardiovasc. Pharm. 1985;7:556-561.
Seraydarian MW, Artaza L: Modification by adenosine of the effect of Adriamycin on myocardial cells in culture. Cancer Research 1979;39:2940-2944.
Saman S, Jacobs P, Opie LH: Mechanism of acute anthracycline cardiotoxicity in isolated rat hearts: Carminomycin versus Daunomycin. Cancer Research 1984;44:1316-1320.
Villani F, Piccinini F, Merelli P, Favalli L: Influence of Adriamycin of calcium exchangeability in cardiac muscle and its modification by ouabain. Chemical Pharm. 1977;27:985-987.
DiMarco A, Dasdia T, Pastori W: Interaction of calcium ions and cAMP on the cytotoxic effect of doxorubicin. Tumori 1984;70:217-221.
Singal PK, Panagia V: Direct effects of Adriamycin on the rat heart sarcolemma. Res. Commun. Chem. Path. Pharm. 1984;43(1):67-72.
Lazarus ML, Rossner KL, Anderson KM: Adriamycin-induced alterations of the action potential in rat papillary muscle. Cardiovasc. Res. 1980;14:446-450.
Azuma J, Serelakis N, Hasegawa H, et al: Adriamycin cardiotoxicity: possible pathogenic mechanisms. J. MoL Cell. Cardiol. 1981;13:381-397.
Mhatre R, Herman E, Huidobro A, Waravdekar V: The possible relationship between metabolism and cardiac toxicity of daunomycin and related compounds. J. Pharm. Exp. Ther. 1971;178:216-222.
Wheeler DMS: Another hypothesis concerning the antitumor activity and cardiotoxicity of daunorubicin (NSC-82151) and Adriamycin (NSC-1 23127). Cancer Chemother. Reports, Part 1 1975;59(2):258259.
Levey GS, Levey BA, Ruiz E, Lehotay DC: Selective inhibition of rat and human cardiac guanylate cyclase in vitro by doxorubicin (Adriamycin): a possible link to anthracycline cardiotoxicity. Cardiol. 1979;1 1:591-599.
Lehotay DC, Levey BA, Rogerson BJ, Levey GS: Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs: possible relationship to cardiotoxicity. Cancer Treat. Reports 1982;66(2):311-316.
Law J, Fumagalli A, Schein PS, Rahman A: Selective inhibition of cardiac cyclic nucleotide phosphodiesterases by doxorubicin and daunorubicin. Life Sciences 1985;36:589-599.
Fiallo MML, Garnier-Suillerot A: Interaction of Adriamycin with cardiolipin-containing vesicles: evidence of an embedded site for t
Green Michael David
Muggia Franco Mario
Speyer James Leonard
New York University
Russel Jeffrey E.
LandOfFree
Reduction of anthracycline-induced cardiotoxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reduction of anthracycline-induced cardiotoxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of anthracycline-induced cardiotoxicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1532050